Epileptic encephalopathy

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
2 Unique sponsors
3 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Phase III: 1 Phase II: 1 Phase I (First in Human): 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • Praxis Precision Medicines Inc. Commercial
    5'-MOEMC-(SP)-MOEMC-(P)-MOEA-(P)-MOEMC-(P)-MOEG-(P)-MOEA-(P)-DMC-(SP)-DA-(SP)-DT-(SP)-DA-(SP)-DT-(SP)-DT-(SP)-DT-(SP)-DT-(SP)-DT-(SP)-DMC-(SP)-MOET-(P)-MOEA-(SP)-MOEMC-(SP)-MOEA 3'
    2024-515598-82-00 2 countries n=25 Orphan
    Pending

Phase II

1 trial
  • Praxis Precision Medicines Inc. Commercial
    RELUTRIGINE
    2022-502298-41-00 1 country 2023 n=70 Orphan
    Ended

Phase I (First in Human)

1 trial
  • Institut De Recherches Internationales Servier IRIS Commercial
    S230815-2
    2024-513332-17-00 3 countries 2025 n=20
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Praxis Precision Medicines Inc. Commercial 2 Phase II, Phase III 0
Institut De Recherches Internationales Servier IRIS Commercial 1 Phase I (First in Human) 1
New trials by year
2023
1
2025
1
← All indication landscapes